期刊文献+

替加环素联合异帕米星治疗多重耐药鲍曼不动杆菌肺炎的疗效观察 被引量:2

下载PDF
导出
摘要 目的探讨替加环素联合异帕米星治疗多重耐药鲍曼不动杆菌肺炎的临床效果。方法选择多重耐药鲍曼不动杆菌肺炎患者66例,随机均分为对照组和治疗组(n=33)。对照组患者给予头孢哌酮舒巴坦治疗,治疗组给予替加环素联合异帕米星治疗,对比分析2组的治疗效果。结果对照组治疗总有效率为72.7%,细菌清除率为36.4%;治疗组治疗总有效率为90.9%,细菌清除率为60.6%,2组治疗总有效率及细菌清除率组间差异有统计学意义(P<0.05)。对照组和治疗组患者不良反应发生率分别是15.1%、9.1%,2组患者的不良反应发生率对比差异无统计学意义。结论采用替加环素联合异帕米星治疗多重耐药鲍曼不动杆菌肺炎,安全性高、不良反应少,临床治疗效果好。
作者 简勇
出处 《当代医学》 2015年第24期130-131,共2页 Contemporary Medicine
  • 相关文献

参考文献8

二级参考文献39

  • 1张中伟,周琰,康焰.呼吸机相关性肺炎的病原学特点及其防治[J].中国呼吸与危重监护杂志,2002,1(4):243-245. 被引量:22
  • 2社区获得性肺炎诊断和治疗指南[J].中华结核和呼吸杂志,2006,29(10):651-655. 被引量:3052
  • 3贾继东,侯金林,尹有宽,徐道振,谭德明,牛俊奇,周霞秋,王宇明,朱理珉,贺永文,任红,万谟彬,陈成伟,巫善明,陈亚岗,许家璋,王勤环,魏来,马红.替比夫定或拉米夫定抗乙型肝炎病毒的疗效预测探讨[J].中华肝脏病杂志,2007,15(5):342-345. 被引量:141
  • 4沈晓明,王卫平.儿科学[M].7版.北京:人民卫生出版社,2007:404.
  • 5Seifer M,Patty A,Serra I,et al Telbivudine,a nucleoside analog inhibitor of HBV polymerase,has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir.Antiviral Res,2009,81(2):147-155.
  • 6Delaney WE 4th,Yang H,Miller MD,et al.Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro.Antimicrob Agents Chemother,2004,48(10):3702-3710.
  • 7Reijnders JG,Leemans WF,Hansen BE,et al.On-treatment monitoring of adefovir therapy in chronic hepatitis B:virologic response can be assessed at 24 weeks.J Viral Hepat,2009,16(2):113-120.
  • 8Fungs K,Lok AS. Management of hepatitis B patient with antiviral resistance. Antivir Ther,2004,9:1013-1026.
  • 9Liaw YF ,Gane E,Leung N,et al. 2-Year GLOBE trial results:tell~ivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology,2009,136:486-495.
  • 10Lai CL. Leung N,Teo EK,et al. A 1-year trial of telbivudine, lamivudine,and the combination in patients with hepatitis B e antigen -positive chronic hepatitis B. Gastroenterology, 2005,129:528-536.

共引文献92

同被引文献45

  • 1Garnacho-Montero J, Amaya-Villar R. Multiresistant Acinetobacter baumannii infections: epidemiology and management[J]. Curt Opin Infect Dis, 2010, 23(4): 332-339.
  • 2Karageorgopoulos D E, Falagas M E. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections[J]. Lancet Infect Dis, 2008, 8(12): 751-762.
  • 3Wang L F, Li J L, Ma W H, et al. Drug resistance analysis of bacterial strains isolated from burn patients[J]. Gen Mol Res Gmr, 2014, 13(4): 9727-9734.
  • 4Chopra T, Marchaim D, Awali R A, et al. Epidemiology of bloodstream infections caused by Acinetobacter baumannii and impact of drug resistance to both carbapenems and ampicillin-sulbactam on clinical outcomes[J]. Antimicrob Agents Chemother, 2013, 57(12): 6270-6275.
  • 5Rose W E, Rybak M J. Tigecycline: first of a new class of antimicrobial agents[J]. Pharmacotherapy, 2006, 26(8): 1099-1110.
  • 6Karageorgopoulos D E, Kelesidis T, Kelesidis I, et al Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infectionsa review of the scientific evidence[J]. J Antimicrob Chemother, 2008, 62(I): 45-55.
  • 7Guner R, Hasanoglu I, Keske S, et al. Outcomes in patients infected with carbapenem-resistant Acinetobacter baumannii and treated with tigecycline alone or in combination therapy[J]. Infection, 2011, 39(6): 515-518.
  • 8Gallagher J C, Rouse H M. Tigecycline for the treatment of Aeinetobaeter infections: a case series[J]. Ann Pharmacother, 2008, 42(9): 1188-1194.
  • 9Wells G A, Shea B, O'Connell D. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses[EB/OL]. 2012. Available at: http: //www. ohri. ca/programs/clinical_epidemiology/oxford. asp[accessed 02.08. 12].
  • 10Poulakou G, Kontopidou F V, Paramythiotou E, et al. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens[J]. J Infect, 2009, 58(4): 273-284.

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部